PDCD1 and non-small cell lung carcinoma: Similar with our CyTOF data, another study showed that a strong predictor for better response to anti‐PD‐1 immunotherapy was the high frequency of CD14+CD16−HLA‐DRhi monocytes in melanoma[22] and non‐small cell lung cancer (NSCLC).[23] These results emphasized our discovery that classical monocytes enact as immune modulators during exposure to immunotherapy and may directly sway responsiveness.